SCHEMBL17625474

SCHEMBL17625474

CC(C)c1ccc(NC(=O)Nc2sc3cc(O)ccc3c2C(N)=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA9 Q16790 2/20 0.43
RAB9A P51151 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 2/20 0.43
NPC1 O15118 2/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
KIF11 P52732 1/20 0.41
KCNH2 Q12809 5/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
MAPK14 Q16539 1/20 0.40
EGFR P00533 1/20 0.39
STING1 Q86WV6 1/20 0.38
AURKA O14965 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5447596 0.87 GAA (0.48) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL5458283 0.85 MEN1 (0.43) CA12CA1CA2CA9RAB9A
SCHEMBL5456326 0.85 MEN1 (0.43) CA12CA1CA2CA9RAB9A
SCHEMBL5451109 0.85 MEN1 (0.56) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL5455604 0.84 MAPT (0.48) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL5460392 0.84 RAB9A (0.49) CA12CA1CA2CA9RAB9A
SCHEMBL5459965 0.83 MDM2 (0.45) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL5446261 0.83 NPC1 (0.47) CA2RAB9AMEN1KMT2AMAPT
SCHEMBL5455862 0.82 BAZ1A (0.51) CA12CA1CA2CA9RAB9A
SCHEMBL5456387 0.82 KMT2A (0.51) RAB9AMEN1KMT2AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170240522-A1 BENZOTHIOPHENE, BENZYLOXYBENZYLIDENE AND INDOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF TUBERCULOSIS ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) 2017-08-24 US disclosed
US-20170240522-A1 BENZOTHIOPHENE, BENZYLOXYBENZYLIDENE AND INDOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF TUBERCULOSIS ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) 2017-08-24 US disclosed
WO-2016041972-A1 BENZOTHIOPHENE, BENZYLOXYBENZYLIDENE AND INDOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF TUBERCULOSIS ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2016-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170240522-A1 BENZOTHIOPHENE, BENZYLOXYBENZYLIDENE AND INDOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF TUBERCULOSIS INMT, IDO2, IDO1 CA12 4723/4885CA1 4875/4885CA2 4194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.